1.1Phospholipid vesicle depot
Phosphatidylcholine and cholesterol form membranes around aqueous chambers that contain the peptide. After injection, membrane reorganization and breakdown open diffusion paths from the chambers into tissue fluid.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Phosphatidylcholine and cholesterol form membranes around aqueous chambers that contain the peptide. After injection, membrane reorganization and breakdown open diffusion paths from the chambers into tissue fluid.
Each milligram of dry microspheres contains 20 micrograms of peptide. The injection delivers the target peptide dose using 50 mg of dry microspheres per milligram of peptide, and the hydrated polymer matrix controls release.
Coaxial droplet formation encloses a peptide-rich inner phase in a PLGA-rich outer phase. Solvent extraction hardens the outer phase into a shell that limits early peptide loss, and pores that form during hydrolysis permit release.
Solvent extraction hardens emulsion droplets containing the single polymer grade into dense microspheres. After injection, water penetrates the matrix, and chain cleavage gradually creates connected pores through which the peptide diffuses.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
GLP-1 receptor agonist microspheres made with one low-viscosity PLGA grade and two high-viscosity PLGA grades sit in an upstream chamber of a perfused pancreatic islet assay. A porous membrane retains the microspheres while allowing dissolved agonist to enter the medium flowing into the islet chamber. The assay records insulin secretion during scheduled glucose pulses and measures agonist concentration in the medium entering the islet chamber.
Polycaprolactone replaces one of the two high-viscosity PLGA grades in a matrix containing low-viscosity PLGA and the remaining high-viscosity PLGA. The three polymers dissolve in dichloromethane, and an aqueous GLP-1 receptor agonist solution disperses in the polymer solution as fine droplets. The resulting emulsion disperses in an aqueous polyvinyl alcohol bath, and solvent extraction hardens the droplets into microspheres. The hydrated PLGA phase and the slower-eroding polycaprolactone phase govern water ingress and peptide release.
Two microsphere populations contain 6 wt% GLP-1 receptor agonist and the same blend of one low-viscosity PLGA grade and two high-viscosity PLGA grades. Wet sieving isolates diameter fractions of 20 to 35 µm and 60 to 85 µm, which are dried and combined at a 25:75 mass ratio. The smaller population supplies more surface area per unit mass, and the larger population provides longer diffusion paths from the particle interior.
A bypass syringe holds freeze-dried GLP-1 receptor agonist microspheres in its front chamber and an aqueous suspending vehicle in its rear chamber. The microspheres contain one low-viscosity PLGA grade and two high-viscosity PLGA grades, while the vehicle contains sodium carboxymethylcellulose and a nonionic surfactant. Plunger travel moves the separating stopper to the bypass channel and transfers the vehicle into the front chamber. Gentle inversion disperses the microspheres before the same syringe delivers the suspension.
GLP-1 receptor agonist microspheres containing one low-viscosity PLGA grade and two high-viscosity PLGA grades are suspended in an aqueous sodium alginate solution. The suspension is cast in a shallow mold and contacted with calcium chloride solution to form a calcium alginate gel around the particles. The gel retains the microspheres, and released agonist diffuses through the hydrated gel into the surrounding fluid. Gel thickness sets the diffusion distance between the embedded microspheres and the surrounding fluid.
A flow-focusing emulsifier forms droplets from a dispersed feed containing the GLP-1 receptor agonist and a blend of one low-viscosity PLGA grade and two high-viscosity PLGA grades. A downstream camera measures droplet diameters before solvent extraction, and a feedback controller adjusts the continuous-phase pump speed to hold the median droplet diameter at a calibrated setpoint. Calibration pairs the measured droplet diameter with the final dried microsphere diameter to account for shrinkage during hardening.
The three grades dissolve in a common organic phase before droplet formation and solvent extraction. The lower-molecular-weight chains in the blend reach water-soluble sizes sooner during hydrolysis, while the higher-molecular-weight fraction maintains the particle matrix longer.
An aqueous solution of a GLP-1 receptor agonist acetate salt forms the inner phase of a water-in-oil-in-water emulsion. The organic phase contains dissolved PLGA, which hardens around the inner droplets as the solvent transfers into the outer aqueous phase.
Dried microspheres contain 8 mg of GLP-1 receptor agonist per 100 mg of total particle mass. A liquid chromatography assay quantifies the peptide after extraction from a weighed sample of the dried microspheres.
The polymer blend contains grades with intrinsic viscosities of 0.20, 0.38, and 0.50 dL/g at a dry polymer mass ratio of 20 to 40 to 40. The grades dissolve together in the organic phase before emulsification and solidify together during solvent extraction.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In other embodiments, the present invention provides pharmaceutical compositions including a pharmaceutically acceptable excipient along with a therapeutically effective amount of a GLP-1 receptor agonist or an incretin mimetic.A · US 2010/0137212 A1 · ¶ 39
The disclosure also provides pharmaceutical compositions comprising the GLP-1 receptor agonist compounds described herein and a pharmaceutically acceptable carrier.B · US 2012/0294855 A1 · ¶ 29
An empty cell means only that no passage was reproduced there.
This invention relates to the use of GLP-1 receptor agonists to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.A · US 2010/0137212 A1 · ¶ 1
Thus, there is a need in the art for alternative or improved methods and compositions to treat short bowel syndrome.A · US 2010/0137212 A1 · ¶ 6
There exists a need in the art to identify therapeutic agents that can be used to enhance the quality of sleep and treat sleep apnea without causing patient discomfort.B · US 2012/0294855 A1 · ¶ 5
Methods for treating obstructive sleep apnea include methods for reducing the severity of obstructive sleep apnea.B · US 2012/0294855 A1 · ¶ 6
patent.fyi, US 2026/0355115 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355115/, SHA-256 efea3eba6a326fbf040fac5fb42c7b7f68e3b4269774f20d144fd9ab7bae1d07